参考文献/References:
[1]Shah SJ,Borlaug BA,Kitzman DW,et al. Research priorities for heart failure with preserved ejection fraction :National Heart,Lung,and Blood Institute Working Group Summary[J]. Circulation,2020,141(12):1001-1026.
[2]Hanna A,Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure[J]. Cardiovasc Drugs Ther,2020,34(6):849-863.
[3]Narayan P,Trikantzopoulos E,Mezzaroma E,et al. The interleukin-1 receptor type I promotes the development of aging-associated cardiomyopathy in mice[J]. Cytokine,2022,151:155811.
[4]Van Tassell BW,Trankle CR,Canada JM,et al. IL-1 blockade in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail,2018,11(8):e005036.
[5]Chia YC,Kieneker LM,van Hassel G,et al. Interleukin 6 and development of heart failure with preserved ejection fraction in the general population[J]. J Am Heart Assoc,2021,10(11):e018549.
[6]Domaszk O,Skwarek A,Wojciechowska M. In search of the holy grail:stem cell therapy as a novel treatment of heart failure with preserved ejection fraction[J]. Int J Mol Sci,2023,24(5):4903.
[7]Frljak S,Poglajen G,Vrtovec B. Cell therapy in heart failure with preserved ejection fraction[J]. Card Fail Rev,2022,8:e08.
[8]Graziani F,Varone F,Crea F,et al. Treating heart failure with preserved ejection fraction:learning from pulmonary fibrosis[J]. Eur J Heart Fail,2018,20(10):1385-1391.
[9]Lewis GA,Dodd S,Clayton D,et al. Pirfenidone in heart failure with preserved ejection fraction:a randomized phase 2 trial[J]. Nat Med,2021,27(8):1477-1482.
[10]Dulce RA,Kanashiro-Takeuchi RM,Takeuchi LM,et al. Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction[J]. Cardiovasc Res,2023,118(18):3586-3601.
[11]Pintalh?o M,Vasques-Nóvoa F,Couto-Viana B,et al. Relaxin-2,pathophysiological insights and outcomes in heart failure with preserved ejection fraction:Findings from the NETDiamond cohort[J]. Int J Cardiol,2022,365:87-90.
[12]Borlaug BA,Koepp KE,Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction[J]. J Am Coll Cardiol,2015,66(15):1672-1682.
[13]Borlaug BA,Anstrom KJ,Lewis GD,et al. National Heart ,Lung,and Blood Institute Heart Failure Clinical Research Network. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction:the INDIE-HFpEF randomized clinical trial[J]. JAMA,2018,320(17):1764-1773.
[14]Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure[J]. J Card Fail,2022,28(5):e1-e167.
[15]Pieske B,Maggioni AP,Lam CSP,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study[J]. Eur Heart J,2017,38(15):1119-1127.
[16]Armstrong PW,Lam CSP,Anstrom KJ,et al. VITALITY-HFpEF Study Group. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction :The VITALITY-HFpEF Randomized Clinical Trial[J]. JAMA,2020,324(15):1512-1521.
[17]Bonderman D,Pretsch I,Steringer-Mascherbauer R,et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1):a randomized,double-blind,placebo-controlled,single-dose study[J]. Chest,2014,146(5):1274-1285.
[18]Dachs TM,Duca F,Rettl R,et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction:the haemoDYNAMIC trial[J]. Eur Heart J,2022,43(36):3402-3413.
[19]Redfield MM,Chen HH,Borlaug BA,et al. RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction :a randomized clinical trial[J]. JAMA,2013,309(12):1268-1277.
[20]Hoendermis ES,Liu LC,Hummel YM,et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension:a randomized controlled trial[J]. Eur Heart J,2015,36(38):2565-2573.
[21]Solomon SD,McMurray JJV,Anand IS,et al.PARAGON-HF investigators and committees. angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med,2019,381(17):1609-1620.
[22]Ledwidge M,Dodd JD,Ryan F,et al. Effect of sacubitril/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction:the PARABLE randomized clinical trial[J]. JAMA Cardiol,2023,8(4):366-375.
[23]Mollace A,Macrì R,Mollace R,et al. Effect of ferric carboxymaltose supplementation in patients with heart failure with preserved ejection fraction:role of attenuated oxidative stress and improved endothelial function[J]. Nutrients,2022,14(23):5057.
[24]Sobirin MA,Herry Y,Sofia SN,et al. Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction[J]. Drug Discov Ther,2019,13(1):38-46.
[25]Samuel TY,Hasin T,Gotsman I,et al. Coenzyme Q10 in the treatment of heart failure with preserved ejection fraction:a prospective,randomized,double-blind,placebo-controlled trial[J]. Drugs R D,2022,22(1):25-33.
[26]Abdellatif M,Trummer-Herbst V,Koser F,et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction[J]. Sci Transl Med,2021,13(580):eabd7064.
[27]van de Bovenkamp AA,Bakermans AJ,Allaart CP,et al. TrimetaziDine as a?Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF):rationale and design of a?placebo-controlled cross-over intervention study[J]. Neth Heart J,2020,28(6):312-319.
[28]Fayyaz AU,Sabbah MS,Dasari S,et al. Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension[J]. Cardiovasc Res,2023,119(1):268-282.
[29]Zhang X,Zhang X,Wang S,et al. Effects of Fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction:a prospective intervention study[J]. Can Respir J,2018,2018:3148259.
[30]Zhang LL,Chen GH,Tang RJ,et al. Levosimendan reverses cardiac malfunction and cardiomyocyte ferroptosis during heart failure with preserved ejection fraction via connexin 43 signaling activation[J]. Cardiovasc Drugs Ther,2023.DOI:10.1007/s10557-023-07441-4.
[31]Burkhoff D,Borlaug BA,Shah SJ,et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF:results of the randomized placebo-controlled HELP trial[J]. JACC Heart Fail,2021,9(5):360-370.
[32]Teerlink JR,Diaz R,Felker GM,et al. GALACTIC-HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction:GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials[J]. Eur J Heart Fail,2020,22(11):2160-2171.
[33]Docherty KF,McMurray JJV,Claggett BL,et al. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level:insights from the GALACTIC-HF trial[J]. Eur J Heart Fail,2023,25(2):248-259.
[34]李红艳,赵思涵,王世华,等.SERCA2a在心力衰竭中的研究进展[J].中国药理学通报,2020,36(2):171-174.
[35]Greenberg B,Butler J,Felker GM,et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2):a randomised,multinational,double-blind,placebo-controlled,phase 2b trial[J]. Lancet,2016,387(10024):1178-1186.
[36]Sarma S,MacNamara JP,Hieda M,et al. SERCA2a agonist effects on cardiac?performance during exercise?in?heart?failure with preserved?ejection fraction[J]. JACC Heart Fail,2023,11(7):760-771.
[37]廖玉华,余淼,袁璟,等.心力衰竭SGLT2抑制剂临床应用的中国专家共识[J].临床心血管病杂志,2022,38(8):599-605.
[38]Anker SD,Butler J,Filippatos GS,et al.EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction:rationale for and design of the EMPEROR-Preserved Trial[J]. Eur J Heart Fail,2019,21(10):1279-1287.
[39]Solomon SD,de Boer RA,DeMets D,et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction:rationale and design of the DELIVER trial[J]. Eur J Heart Fail,2021,23(7):1217-1225.
[40]Bhatt DL,Szarek M,Steg PG,et al.SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure[J]. N Engl J Med,2021,384(2):117-128.
[41]Cowart K,Carris NW. Evaluation of cardiovascular and renal outcomes with ertugliflozin:what is the VERdict from the VERTIS-CV trial?[J]. Expert Opin Pharmacother ,2021,22(2):163-165.
[42]Ueda T,Kasama S,Yamamoto M,et al.CANONICAL Study Group. Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes [J]. Circ Rep,2021,3(8):440-448.
相似文献/References:
[1]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(10):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[2]唐欣 罗素新.心房颤动合并 射血分数保留的心力衰竭的研究进展[J].心血管病学进展,2019,(5):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]
TANG Xin,LUO Suxin.Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(10):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]
[3]李海威 姜红 李宪伦.射血分数保留性心力衰竭患者运动康复的研究进展[J].心血管病学进展,2019,(8):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
LI Haiwei,JIANG Hong,LI Xianlun.Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(10):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
[4]李可 田进文 邓珏琳.老年高血压的临床诊治研究进展[J].心血管病学进展,2019,(9):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
LI Ke,TIAN Jinwen,DENG Juelin.Diagnosis and Treatment in Elderly Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
[5]罗芩 何庆.TNF凝集素样结构域：高原肺水肿药物治疗新选择罗芩 何庆2[J].心血管病学进展,2019,(9):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
LUO QinHE Qing.The Lectin-like Domain of TNF:New Drug Treatment Option for HAPE[J].Advances in Cardiovascular Diseases,2019,(10):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
[6]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(10):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[7]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(10):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[8]杨鹏辉 李谧.巨大动脉导管未闭治疗研究进展[J].心血管病学进展,2021,(1):68.[doi:10.16806/j.cnki.issn.1004-3934.20.01.000]
YANG Penghui,LI Mi.Treatment of Large Patent Ductus Arteriosus[J].Advances in Cardiovascular Diseases,2021,(10):68.[doi:10.16806/j.cnki.issn.1004-3934.20.01.000]
[9]王毅 佘强.射血分数降低性心力衰竭的药物进展[J].心血管病学进展,2021,(11):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WANG Yi,SHE Qiang.Advancement of Drug Therapy in Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(10):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[10]于筱斋?高艳香?郭紫玉?陈西霞?叶子翔?郑金刚.非阻塞性冠状动脉疾病的冠状动脉微循环功能障碍治疗新进展[J].心血管病学进展,2022,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]
YU Xiaozhai,GAO Yanxiang,GUO Ziyu,et al.Treatment of Coronary Microvascular Dysfunction in Non-Obstructive Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2022,(10):385.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]